Lars Einar French
Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections.
Schmitt C, Hoefsmit E, Fangmeier T, Kramer N, Kabakci C, González-Navajas J, Versluis J, Compter A, Harrer T, Mijočević H, Schubert S, Hundsberger T, Menzies A, Scolyer R, Long G, French L, Blank C, Heinzerling L. Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections. Cancer Immunol Immunother 2023
Aug 22, 2023Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections.
Aug 22, 2023Cancer Immunol Immunother 2023
Schmitt Christina, Hoefsmit E P, Fangmeier T, Kramer N, Kabakci C, González-Navajas Jose M, Versluis Judith M, Compter Annette, Harrer T, Mijočević H, Schubert Steffen, Hundsberger Thomas, Menzies A M, Scolyer Richard A, Long Georgina V, French Lars Einar, Blank Christian U, Heinzerling Lucie M
Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome
Mehra T, Guenova E, French L, Dummer R, Hoetzenecker W, Haralambieva E, Schanz U, Nair G, Benz R, Moos R, Ikenberg K, Cozzio A. Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome. JAMA Dermatol 2015; 151:73-7.
Jan 1, 2015Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome
Jan 1, 2015JAMA Dermatol 2015; 151:73-7
Mehra Tarun, Guenova Emmanuella, French Lars Einar, Dummer Reinhard, Hoetzenecker Wolfram, Haralambieva Eugenia, Schanz Urs, Nair Gayathri, Benz Rudolf, Moos Rudolf Maria, Ikenberg Kristian, Cozzio Antonio